BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Acute Myeloid Leukemia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Acute Myeloid Leukemi
 a\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03850574-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03850574)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Clinic
 al Trial to Evaluate the Safety\, Tolerability\, Pharmacokinetics and Phar
 macodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refracto
 ry Acute Myeloid Leukemia\nEstimated primary completion: November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03850574
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03850574-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT03850574)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Clini
 cal Trial to Evaluate the Safety\, Tolerability\, Pharmacokinetics and Pha
 rmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refract
 ory Acute Myeloid Leukemia\nEstimated primary completion: November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03850574
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03850574-3101@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tuspetinib: Phase 1/2 readout est. (NCT03850574)
DESCRIPTION:Tuspetinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Clinic
 al Trial to Evaluate the Safety\, Tolerability\, Pharmacokinetics and Phar
 macodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refracto
 ry Acute Myeloid Leukemia\nEstimated primary completion: November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tuspetinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03850574
URL:https://assetmemo.bio/drug/tuspetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04990102-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vyxeos: Phase 1/2 readout est. (NCT04990102)
DESCRIPTION:Vyxeos\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Phase IB/I
 I of CPX-351 for Relapse Prevention in AML\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vyxeos
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT049
 90102
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987058-2851@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Romaciclib: Phase 2 readout est. (NCT06987058)
DESCRIPTION:Romaciclib\, phase 2\, Acute Myeloid Leukemia.\nStudy: RVU120 R
 ollover Study\nEstimated primary completion: December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/romaciclib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06987058
URL:https://assetmemo.bio/drug/romaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05955261-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT05955261)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Stud
 y of Venetoclax in Combination With Conventional Chemotherapy in Pediatric
  Patients With Acute Myeloid Leukemia\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gilteritini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 955261
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05955261-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05955261)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Venetoclax in Combination With Conventional Chemotherapy in Pediatric P
 atients With Acute Myeloid Leukemia\nEstimated primary completion: Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059552
 61
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783790-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06783790)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Avapriti
 nib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed 
 AML After Allo-HSCT\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06783790
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05788679-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05788679)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects Wit
 h MDS\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05788679
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05955261-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05955261)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Venetoclax in Combination With Conventional Chemotherapy in Pediatric 
 Patients With Acute Myeloid Leukemia\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0595
 5261
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783790-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06783790)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Avaprit
 inib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed
  AML After Allo-HSCT\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06783790
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05360160-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05360160)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phas
 e I-II Study Investigating the All-Oral Combination of the Menin Inhibitor
  SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute 
 Myeloid Leukemia (SAVE)\nEstimated primary completion: 1 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05360160
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05360160-2362@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1/2 readout est. (NCT053601
 60)
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1/2\, Acute Myeloid Le
 ukemia.\nStudy: A Phase I-II Study Investigating the All-Oral Combination 
 of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) an
 d Venetoclax in Acute Myeloid Leukemia (SAVE)\nEstimated primary completio
 n: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 ecitabine-cedazuridine-inqovi#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05360160
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05360160-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT05360160)
DESCRIPTION:Revumenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phase
  I-II Study Investigating the All-Oral Combination of the Menin Inhibitor 
 SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute M
 yeloid Leukemia (SAVE)\nEstimated primary completion: 1 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05360160
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06220162-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06220162)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: VAC Regi
 men for AML Patients Who Failed to Response to VA Regimen\nEstimated prima
 ry completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06220162
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06635681-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06635681)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Efficacy
  of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups
  of AML\nEstimated primary completion: 1 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06635681
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06220162-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06220162)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: VAC Reg
 imen for AML Patients Who Failed to Response to VA Regimen\nEstimated prim
 ary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06220162
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06635681-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06635681)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Efficac
 y of Venetoclax Combined With Intensive Chemotherapy in Different Subgroup
 s of AML\nEstimated primary completion: 1 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06635681
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07712848-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07712848)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: DEC3-VEN
  vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML\nEstimated pr
 imary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07712848
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04588922-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04588922)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study 
 of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Pa
 tients With Hematologic Malignancies and High-Risk Newly Diagnosed AML\nEs
 timated primary completion: 30 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04588922
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284486-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06284486)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Mult
 i-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhib
 ition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and
  Revumenib\nEstimated primary completion: 30 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06284486
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04588922-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04588922)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in P
 atients With Hematologic Malignancies and High-Risk Newly Diagnosed AML\nE
 stimated primary completion: 30 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04588922
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284486-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT06284486)
DESCRIPTION:Revumenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Multi
 -Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibi
 tion of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and 
 Revumenib\nEstimated primary completion: 30 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/revumenib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06284486
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04588922-3077@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tambiciclib: Phase 1/2 readout est. (NCT04588922)
DESCRIPTION:Tambiciclib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in P
 atients With Hematologic Malignancies and High-Risk Newly Diagnosed AML\nE
 stimated primary completion: 30 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tambiciclib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04588922
URL:https://assetmemo.bio/drug/tambiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06451861-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06451861)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Randomiz
 ed Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy 
 or AB-14 for ND AML\nEstimated primary completion: 30 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06451861
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06451861-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06451861)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Randomi
 zed Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy
  or AB-14 for ND AML\nEstimated primary completion: 30 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06451861
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264010-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07264010)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Sorafe
 nib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML:
  a Prospective\, Single-arm\, Multicenter Clinical Study\nEstimated primar
 y completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07264010
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00392353-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT00392353)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Vorin
 ostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes 
 or Acute Myeloid Leukemia\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT00392353
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05584761-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05584761)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Unrel
 ated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatm
 ent for Advanced MDS\,CMML-2 and sAML\nEstimated primary completion: 31 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitid
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05584761
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04128501-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04128501)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post
 -Transplant Setting\nEstimated primary completion: 31 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04128501
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04128501-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT04128501)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Pos
 t-Transplant Setting\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04128501
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03629171-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03629171)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Liposome
 -encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participa
 nts With Relapsed\, Refractory or Untreated Acute Myeloid Leukemia\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03629171
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06621212-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06621212)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Mitoxant
 rone Hydrochloride Liposome\, Standard-dose of Cytarabine and Venetoclax i
 n the Treatment of R/R AML\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06621212
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03737955-2842@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT03737955)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Dise
 ase in Patients With Acute Myeloid Leukemia\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ge
 mtuzumab-ozogamicin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03737955
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03629171-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vyxeos: Phase 2 readout est. (NCT03629171)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: Liposome-enc
 apsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants 
 With Relapsed\, Refractory or Untreated Acute Myeloid Leukemia\nEstimated 
 primary completion: 31 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03629171
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486479-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07486479)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax\, Azacitidine\, and Mitoxantrone Hydrochloride Liposome Versus Idarubic
 in and Cytarabine in Newly Diagnosed AML\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venet
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07486479
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486479-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07486479)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax\, Azacitidine\, and Mitoxantrone Hydrochloride Liposome Versus Idarubi
 cin and Cytarabine in Newly Diagnosed AML\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azac
 itidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07486479
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990321-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 3 readout est. (NCT06990321)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Effectiv
 eness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation
  Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid 
 Leukemia\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06990321
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06345365-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 3 readout est. (NCT06345365)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: MA+AZA 
 Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06345365
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06384261-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06384261)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Az
 acitidine in Newly Diagnosed AML Ineligible for Intensive Therapy\nEstimat
 ed primary completion: January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06384261
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06384261-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06384261)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and A
 zacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy\nEstima
 ted primary completion: January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06384261
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06384261-3085@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cusatuzumab: Phase 2 readout est. (NCT06384261)
DESCRIPTION:Cusatuzumab\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and A
 zacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy\nEstima
 ted primary completion: January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cusatuzumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06384261
URL:https://assetmemo.bio/drug/cusatuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06773208-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06773208)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06773208
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06773208-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06773208)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
 \nEstimated primary completion: January 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06773208
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04801797-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04801797)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax + Azacitidine vs. Induction Chemotherapy in AML\nEstimated primary comp
 letion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04801797
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04801797-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Azacitidine: Phase 2 readout est. (NCT04801797)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax + Azacitidine vs. Induction Chemotherapy in AML\nEstimated primary com
 pletion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04801797
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04801797-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Vyxeos: Phase 2 readout est. (NCT04801797)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoclax +
  Azacitidine vs. Induction Chemotherapy in AML\nEstimated primary completi
 on: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 yxeos#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04801797
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754540-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06754540)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Azaciti
 dine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Po
 st-transplant Relapse Prevention.\nEstimated primary completion: 1 January
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067545
 40
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03728335-2867@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT03728335)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2
  Mutation\nEstimated primary completion: 11 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03728335
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03862157-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03862157)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Azacit
 idine\, Venetoclax\, and Pevonedistat in Treating Patients With Newly Diag
 nosed Acute Myeloid Leukemia\nEstimated primary completion: 31 January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03862157
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03862157-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT03862157)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Azaci
 tidine\, Venetoclax\, and Pevonedistat in Treating Patients With Newly Dia
 gnosed Acute Myeloid Leukemia\nEstimated primary completion: 31 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03862157
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04086264-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04086264)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: IMGN63
 2 as Monotherapy or With Venetoclax and/or Azacitidine for Participants Wi
 th CD123-Positive Acute Myeloid Leukemia\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4086264
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04086264-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04086264)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: IMGN6
 32 as Monotherapy or With Venetoclax and/or Azacitidine for Participants W
 ith CD123-Positive Acute Myeloid Leukemia\nEstimated primary completion: F
 ebruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaciti
 dine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04086264
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04086264-2846@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Decnupaz (Pivekimab Sunirine): Phase 1/2 readout est. (NCT04086264)
DESCRIPTION:Decnupaz (Pivekimab Sunirine)\, phase 1/2\, Acute Myeloid Leuke
 mia.\nStudy: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine 
 for Participants With CD123-Positive Acute Myeloid Leukemia\nEstimated pri
 mary completion: February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pivekimab-sunirine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04086264
URL:https://assetmemo.bio/drug/pivekimab-sunirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183035-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 3 readout est. (NCT05183035)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax in Children With Relapsed Acute Myeloid Leukemia (AML)\nEstimated prima
 ry completion: February 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05183035
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183035-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Azacitidine: Phase 3 readout est. (NCT05183035)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax in Children With Relapsed Acute Myeloid Leukemia (AML)\nEstimated prim
 ary completion: February 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05183035
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183035-2842@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Gemtuzumab Ozogamicin: Phase 3 readout est. (NCT05183035)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 3\, Acute Myeloid Leukemia.\nStud
 y: Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)\nEsti
 mated primary completion: February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05183035
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03383575-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Azacitidine: Phase 2 readout est. (NCT03383575)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Azaciti
 dine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic 
 Syndrome\nEstimated primary completion: 28 February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03383575
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03383575-2867@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT03383575)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodys
 plastic Syndrome\nEstimated primary completion: 28 February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03383575
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428969-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05428969)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stud
 y to Assess Safety\, Tolerability and Preliminary Efficacy of Bexmarilimab
  in Combination With Standard of Care in Patients With Hematological Malig
 nancies\nEstimated primary completion: March 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05428969
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428969-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05428969)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy to Assess Safety\, Tolerability and Preliminary Efficacy of Bexmarilima
 b in Combination With Standard of Care in Patients With Hematological Mali
 gnancies\nEstimated primary completion: March 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05428969
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428969-2934@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bexmarilimab: Phase 1/2 readout est. (NCT05428969)
DESCRIPTION:Bexmarilimab\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A St
 udy to Assess Safety\, Tolerability and Preliminary Efficacy of Bexmarilim
 ab in Combination With Standard of Care in Patients With Hematological Mal
 ignancies\nEstimated primary completion: March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bexmarilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05428969
URL:https://assetmemo.bio/drug/bexmarilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06129734-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06129734)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Decita
 bine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allo
 graft Stem Cell Transplant\nEstimated primary completion: March 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06129734
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118788-2871@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:BG1805: Phase 1/2 readout est. (NCT06118788)
DESCRIPTION:BG1805\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Phase I Cl
 inical Study: BG1805 Injection in the Treatment of Relapsed or Refractory 
 Acute Myeloid Leukemia\nEstimated primary completion: March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bg1805#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06118788
URL:https://assetmemo.bio/drug/bg1805#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623616-2835@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ziftomenib: Phase 2 readout est. (NCT07623616)
DESCRIPTION:Ziftomenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase 
 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM
 1-Mutated Acute Myeloid Leukemia\nEstimated primary completion: March 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07623616
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504458-3093@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Arsenic trioxide (QTX-2101): Phase 3 readout est. (NCT07504458)
DESCRIPTION:Arsenic trioxide (QTX-2101)\, phase 3\, Acute Myeloid Leukemia.
 \nStudy: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Pa
 tients With Acute Promyelocytic Leukemia\nEstimated primary completion: Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/arsenic-tri
 oxide-qtx-2101#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07504458
URL:https://assetmemo.bio/drug/arsenic-trioxide-qtx-2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study 
 to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated 
 primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated
  primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-2849@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Inobrodib: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Inobrodib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study t
 o Evaluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated p
 rimary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/inobrodib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/inobrodib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554406-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05554406)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing 
 New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagn
 osed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)\nEs
 timated primary completion: 31 March 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05554406
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672146-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06672146)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Comparin
 g New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia Th
 at Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06672146
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554406-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05554406)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing
  New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diag
 nosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)\nE
 stimated primary completion: 31 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05554406
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672146-2867@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT06672146)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Le
 ukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)\nEstima
 ted primary completion: 31 March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/enasidenib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06672146
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554406-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Vyxeos: Phase 2 readout est. (NCT05554406)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing New 
 Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed
  and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)\nEstima
 ted primary completion: 31 March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05554406
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04385290-2842@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Gemtuzumab Ozogamicin: Phase 1/2 readout est. (NCT04385290)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 1/2\, Acute Myeloid Leukemia.\nSt
 udy: Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line St
 andard Therapy for Acute Myeloid Leukemia (MOSAIC)\nEstimated primary comp
 letion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/g
 emtuzumab-ozogamicin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04385290
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04385290-2843@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Rydapt (Midostaurin): Phase 1/2 readout est. (NCT04385290)
DESCRIPTION:Rydapt (Midostaurin)\, phase 1/2\, Acute Myeloid Leukemia.\nStu
 dy: Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Sta
 ndard Therapy for Acute Myeloid Leukemia (MOSAIC)\nEstimated primary compl
 etion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mi
 dostaurin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04385290
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07537257-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07537257)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: VEN+ID
 AC vs IDAC in AML\nEstimated primary completion: 1 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07537257
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03503409-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270402
DTEND;VALUE=DATE:20270403
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT03503409)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Sy
 ndrome\nEstimated primary completion: 2 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03503409
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03839771-2867@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270417
DTEND;VALUE=DATE:20270418
SUMMARY:Idhifa (Enasidenib): Phase 3 readout est. (NCT03839771)
DESCRIPTION:Idhifa (Enasidenib)\, phase 3\, Acute Myeloid Leukemia.\nStudy:
  A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy
  and Consolidation Therapy\, Followed by Maintenance Therapy in Patients W
 ith Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2\,
  With an IDH1 or IDH2 Mutation\, Respectively\, Eligible for Intensive Che
 motherapy\nEstimated primary completion: 17 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03839771
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03839771-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270417
DTEND;VALUE=DATE:20270418
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT03839771)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3\, Acute Myeloid Leukemia.\nStudy
 : A Study of Ivosidenib or Enasidenib in Combination With Induction Therap
 y and Consolidation Therapy\, Followed by Maintenance Therapy in Patients 
 With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2\
 , With an IDH1 or IDH2 Mutation\, Respectively\, Eligible for Intensive Ch
 emotherapy\nEstimated primary completion: 17 April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03839771
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03586609-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03586609)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax\, Cladribine\, Low Dose Cytarabine\, and Azacitidine in Treating Patien
 ts With Previously Untreated Acute Myeloid Leukemia\nEstimated primary com
 pletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03586609
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03586609-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Azacitidine: Phase 2 readout est. (NCT03586609)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax\, Cladribine\, Low Dose Cytarabine\, and Azacitidine in Treating Patie
 nts With Previously Untreated Acute Myeloid Leukemia\nEstimated primary co
 mpletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03586609
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05429632-2980@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:mocravimod: Phase 3 readout est. (NCT05429632)
DESCRIPTION:mocravimod\, phase 3\, Acute Myeloid Leukemia.\nStudy: Mocravim
 od as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo
 -HCT\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/mocravimod#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05429632
URL:https://assetmemo.bio/drug/mocravimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793478-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Quizartinib: Phase 1/2 readout est. (NCT03793478)
DESCRIPTION:Quizartinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Safet
 y and Efficacy of Quizartinib in Children and Young Adults With Acute Myel
 oid Leukemia (AML)\, a Cancer of the Blood\nEstimated primary completion: 
 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/quizartin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3793478
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07607418-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07607418)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated 
 AML and HR-MDS\nEstimated primary completion: 30 May 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07607418
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04049539-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Vyxeos: Phase 1/2 readout est. (NCT04049539)
DESCRIPTION:Vyxeos\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Vyxeos for
  Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent
  Disease After Induction\nEstimated primary completion: 31 May 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/vyxeos#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04049539
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975919-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04975919)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax in Combination With Decitabine and Cedazuridine for the Treatment of Re
 lapsed or Refractory Acute Myeloid Leukemia\nEstimated primary completion:
  31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04975919
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548710-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT07548710)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study 
 of SA+X in the Treatment of Newly Diagnosed AML\nEstimated primary complet
 ion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gil
 teritinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07548710
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548710-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07548710)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study o
 f SA+X in the Treatment of Newly Diagnosed AML\nEstimated primary completi
 on: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azac
 itidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07548710
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548710-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Quizartinib: Phase 2 readout est. (NCT07548710)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study o
 f SA+X in the Treatment of Newly Diagnosed AML\nEstimated primary completi
 on: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/quiz
 artinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07548710
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548710-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07548710)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Study of SA+X in the Treatment of Newly Diagnosed AML\nEstimated primary
  completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ivosidenib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07548710
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548710-2909@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07548710)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Study of SA+X in the Treatment of Newly Diagnosed AML\nEstimated primar
 y completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sonrotoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07548710
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03897127-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vyxeos: Phase 3 readout est. (NCT03897127)
DESCRIPTION:Vyxeos\, phase 3\, Acute Myeloid Leukemia.\nStudy: Study of Sta
 ndard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in
  Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Gene
 tics\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03897127
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296445-3116@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Arsenic trioxide (SDK001): Phase 3 readout est. (NCT07296445)
DESCRIPTION:Arsenic trioxide (SDK001)\, phase 3\, Acute Myeloid Leukemia.\n
 Study: A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to 
 Intravenous Arsenic Trioxide in Pharmacokinetics\, Safety\, and Efficacy (
 LATITUDE/SDKARS-301)\nEstimated primary completion: June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/arsenic-trioxide-sdk001#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07296445
URL:https://assetmemo.bio/drug/arsenic-trioxide-sdk001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988555-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gilteritinib: Phase 1/2 readout est. (NCT04988555)
DESCRIPTION:Gilteritinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Ph
 ase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Hor
 izen-1)\nEstimated primary completion: 30 June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04988555
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988555-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04988555)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phas
 e 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horiz
 en-1)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04988555
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988555-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04988555)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Pha
 se 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Hori
 zen-1)\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04988555
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988555-3087@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Enzomenib: Phase 1/2 readout est. (NCT04988555)
DESCRIPTION:Enzomenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phase
  1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horize
 n-1)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/enzomenib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04988555
URL:https://assetmemo.bio/drug/enzomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06429098-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06429098)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study of
  A Venetoclax-based\, Anthracycline-free Regimen in Newly Diagnosed CBFβ:
 :MYH11(+) AML\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06429098
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06429098-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06429098)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study o
 f A Venetoclax-based\, Anthracycline-free Regimen in Newly Diagnosed CBFβ
 ::MYH11(+) AML\nEstimated primary completion: 30 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06429098
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04050280-2842@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT04050280)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: CLAG-GO for Patients With Persistent\, Relapsed or Refractory AML\nEsti
 mated primary completion: 30 June 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04050280
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06281847-3076@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:CCTx-001: Phase 1/2 readout est. (NCT06281847)
DESCRIPTION:CCTx-001\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: An Adapt
 ive Open-label Multicentre Phase 1/2 Trial\, to Determine the Recommended 
 Phase 2 Dose of CCTx-001\, and to Assess Safety\, Tolerability\, and Clini
 cal Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia\
 nEstimated primary completion: July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cctx-001#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06281847
URL:https://assetmemo.bio/drug/cctx-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05876832-2879@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:XY0206: Phase 3 readout est. (NCT05876832)
DESCRIPTION:XY0206\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study of X
 Y0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory 
 AML With FLT3-ITD-Mutation (ALIVE)\nEstimated primary completion: 1 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/xy0206#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05876832
URL:https://assetmemo.bio/drug/xy0206#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191263-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06191263)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Safety a
 nd Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/R
 efractory AML\nEstimated primary completion: August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06191263
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07214064-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07214064)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allog
 eneic Stem Cell Transplantation\nEstimated primary completion: August 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07214064
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191263-2851@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Romaciclib: Phase 2 readout est. (NCT06191263)
DESCRIPTION:Romaciclib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Safety a
 nd Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/R
 efractory AML\nEstimated primary completion: August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/romaciclib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06191263
URL:https://assetmemo.bio/drug/romaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844048-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03844048)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: An Exten
 sion Study of Venetoclax for Subjects Who Have Completed a Prior Venetocla
 x Clinical Trial\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03844048
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532552-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06532552)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Comparis
 on of VA (Venetoclax\, Azacitidine)\, VACl (VA\, Cladribine)\, VACh (VA\, 
 Chidamide)\, and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Le
 ukemia\nEstimated primary completion: 1 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06532552
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532552-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06532552)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Compari
 son of VA (Venetoclax\, Azacitidine)\, VACl (VA\, Cladribine)\, VACh (VA\,
  Chidamide)\, and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid L
 eukemia\nEstimated primary completion: 1 August 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06532552
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132684-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07132684)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Comparis
 on of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia
  Patients\nEstimated primary completion: 30 August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07132684
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132684-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07132684)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Compari
 son of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemi
 a Patients\nEstimated primary completion: 30 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07132684
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07726576-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07726576)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid
  Leukemia\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07726576
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07726576-2843@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rydapt (Midostaurin): Phase 1/2 readout est. (NCT07726576)
DESCRIPTION:Rydapt (Midostaurin)\, phase 1/2\, Acute Myeloid Leukemia.\nStu
 dy: Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acu
 te Myeloid Leukemia\nEstimated primary completion: September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/midostaurin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07726576
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07451912-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07451912)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mut
 ated AML\nEstimated primary completion: September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07451912
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07761533-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07761533)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: PBSS1
 113 in Combination With Azacitidine to Treat Patients With AML/MDS\nEstima
 ted primary completion: September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07761533
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05322850-2880@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:OrcaGraft (Orca-Q): Phase 1/2 readout est. (NCT05322850)
DESCRIPTION:OrcaGraft (Orca-Q)\, phase 1/2\, Acute Myeloid Leukemia.\nStudy
 : Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopo
 ietic Cell Transplant (HCT)\nEstimated primary completion: September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/orcagraft-orca-q#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0532285
 0
URL:https://assetmemo.bio/drug/orcagraft-orca-q#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07813390-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07813390)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Homohar
 ringtonine\, Lisaftoclax\, and Azacitidine for AML After Venetoclax-Based 
 Therapy Failure\nEstimated primary completion: 1 September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07813390
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07813390-2883@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT07813390)
DESCRIPTION:Lisaftoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Homohar
 ringtonine\, Lisaftoclax\, and Azacitidine for AML After Venetoclax-Based 
 Therapy Failure\nEstimated primary completion: 1 September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07813390
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743112-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07743112)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase 
 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit New
 ly Diagnosed Acute Myeloid Leukemia\nEstimated primary completion: 1 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 43112
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743112-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07743112)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase
  2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Ne
 wly Diagnosed Acute Myeloid Leukemia\nEstimated primary completion: 1 Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7743112
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03683433-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:Azacitidine: Phase 2 readout est. (NCT03683433)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Enaside
 nib and Azacitidine in Treating Patients With Recurrent or Refractory Acut
 e Myeloid Leukemia and IDH2 Gene Mutation\nEstimated primary completion: 2
 0 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aza
 citidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03683433
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03683433-2867@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT03683433)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  Enasidenib and Azacitidine in Treating Patients With Recurrent or Refract
 ory Acute Myeloid Leukemia and IDH2 Gene Mutation\nEstimated primary compl
 etion: 20 September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/enasidenib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03683433
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03214562-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03214562)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax With Combination Chemotherapy in Treating Patients With Newly Diagnos
 ed or Relapsed or Refractory Acute Myeloid Leukemia\nEstimated primary com
 pletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03214562
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03471260-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03471260)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Ivosid
 enib and Venetoclax With or Without Azacitidine in Treating Patients With 
 IDH1 Mutated Hematologic Malignancies\nEstimated primary completion: 30 Se
 ptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03471260
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03471260-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT03471260)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Ivosi
 denib and Venetoclax With or Without Azacitidine in Treating Patients With
  IDH1 Mutated Hematologic Malignancies\nEstimated primary completion: 30 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacit
 idine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03471260
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03471260-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tibsovo (Ivosidenib): Phase 1/2 readout est. (NCT03471260)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 1/2\, Acute Myeloid Leukemia.\nStu
 dy: Ivosidenib and Venetoclax With or Without Azacitidine in Treating Pati
 ents With IDH1 Mutated Hematologic Malignancies\nEstimated primary complet
 ion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ivosidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03471260
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05401097-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05401097)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: IDH Targ
 eted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatmen
 t of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive
  Induction Therapy (I- DATA Study)\nEstimated primary completion: 30 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 01097
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05401097-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05401097)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: IDH Tar
 geted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatme
 nt of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensiv
 e Induction Therapy (I- DATA Study)\nEstimated primary completion: 30 Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5401097
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05401097-2867@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT05401097)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the
  Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for 
 Intensive Induction Therapy (I- DATA Study)\nEstimated primary completion:
  30 September 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 nasidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05401097
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05401097-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT05401097)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in th
 e Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for
  Intensive Induction Therapy (I- DATA Study)\nEstimated primary completion
 : 30 September 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ivosidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05401097
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514936-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07514936)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients
  With Acute Myeloid Leukaemia\nEstimated primary completion: 30 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07514936
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514936-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07514936)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patient
 s With Acute Myeloid Leukaemia\nEstimated primary completion: 30 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075149
 36
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486726-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07486726)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Aclaru
 bicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myelo
 id Leukemia\nEstimated primary completion: October 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07486726
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486726-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07486726)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Aclar
 ubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myel
 oid Leukemia\nEstimated primary completion: October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07486726
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561152-2839@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tagraxofusp: Phase 1/2 readout est. (NCT06561152)
DESCRIPTION:Tagraxofusp\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Tagra
 xofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refra
 ctory AML\nEstimated primary completion: October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tagraxofusp#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06561152
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07163793-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07163793)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Pilot St
 udy of Reduced Venetoclax Exposure\nEstimated primary completion: October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07163793
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07163793-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07163793)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Pilot S
 tudy of Reduced Venetoclax Exposure\nEstimated primary completion: October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071637
 93
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06511882-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06511882)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Disconti
 nuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD\n
 Estimated primary completion: October 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06511882
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06511882-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06511882)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Discont
 inuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD\
 nEstimated primary completion: October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06511882
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06235801-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Gilteritinib: Phase 1/2 readout est. (NCT06235801)
DESCRIPTION:Gilteritinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Ph
 ase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed 
 or Refractory FLT3-Mutated Acute Myeloid Leukemia\nEstimated primary compl
 etion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/gilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06235801
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504459-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06504459)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax in Combination With Cladribine and Cytarabine Alternating With Azacitid
 ine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and
  Active Signaling Mutated AML\nEstimated primary completion: 11 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06504459
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504459-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06504459)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax in Combination With Cladribine and Cytarabine Alternating With Azaciti
 dine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML an
 d Active Signaling Mutated AML\nEstimated primary completion: 11 October 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06504459
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907057-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Azacitidine: Phase 3 readout est. (NCT05907057)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: An Open
 -label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adu
 lt Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Inelig
 ible for Intensive Induction Chemotherapy.\nEstimated primary completion: 
 15 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azac
 itidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05907057
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907057-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT05907057)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3\, Acute Myeloid Leukemia.\nStudy
 : An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidi
 ne in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AM
 L) Ineligible for Intensive Induction Chemotherapy.\nEstimated primary com
 pletion: 15 October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ivosidenib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05907057
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02250937-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02250937)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax and Sequential Busulfan\, Cladribine\, and Fludarabine Phosphate Before
  Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Le
 ukemia or Myelodysplastic Syndrome\nEstimated primary completion: 31 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02250
 937
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497062-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06497062)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Phase I
 I Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newl
 y Diagnosed Acute Myeloid Leukemia\nEstimated primary completion: 31 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0649
 7062
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497062-2909@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06497062)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatme
 nt of Newly Diagnosed Acute Myeloid Leukemia\nEstimated primary completion
 : 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/so
 nrotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06497062
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660368-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06660368)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: BCL2i CL
 AG-M in R/R Acute Myeloid Leukemia\nEstimated primary completion: November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0666036
 8
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216443-2968@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:TREGZI (Orca-T): Phase 2 readout est. (NCT07216443)
DESCRIPTION:TREGZI (Orca-T)\, phase 2\, Acute Myeloid Leukemia.\nStudy: Tri
 al of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning 
 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome\nEstim
 ated primary completion: November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/orca-t#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07216443
URL:https://assetmemo.bio/drug/orca-t#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07719348-2719@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:S241656: Phase 1/2 readout est. (NCT07719348)
DESCRIPTION:S241656\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study t
 o Evaluate S241656 Alone or in Combination in Participants With Selected M
 yeloid Malignancies\nEstimated primary completion: 1 November 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/s241656#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07719348
URL:https://assetmemo.bio/drug/s241656#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04256317-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT04256317)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Mult
 i-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplas
 m Alone or in Combination With Venetoclax in AML (AZTOUND Study)\nEstimate
 d primary completion: 1 November 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04256317
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04256317-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT04256317)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Mul
 ti-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neopla
 sm Alone or in Combination With Venetoclax in AML (AZTOUND Study)\nEstimat
 ed primary completion: 1 November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04256317
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917911-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271125
DTEND;VALUE=DATE:20271126
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06917911)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing 
 the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatmen
 t Regimen (Cytarabine and Daunorubicin\, "7+3") for Core Binding Factor Ac
 ute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment
  Trial)\nEstimated primary completion: 25 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06917911
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917911-2842@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271125
DTEND;VALUE=DATE:20271126
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT06917911)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usu
 al Treatment Regimen (Cytarabine and Daunorubicin\, "7+3") for Core Bindin
 g Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATC
 H Treatment Trial)\nEstimated primary completion: 25 November 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06917911
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04774393-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271129
DTEND;VALUE=DATE:20271130
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04774393)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Decita
 bine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enaside
 nib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia\nEs
 timated primary completion: 29 November 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04774393
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04774393-2867@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271129
DTEND;VALUE=DATE:20271130
SUMMARY:Idhifa (Enasidenib): Phase 1/2 readout est. (NCT04774393)
DESCRIPTION:Idhifa (Enasidenib)\, phase 1/2\, Acute Myeloid Leukemia.\nStud
 y: Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib o
 r Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leu
 kemia\nEstimated primary completion: 29 November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04774393
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04774393-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271129
DTEND;VALUE=DATE:20271130
SUMMARY:Tibsovo (Ivosidenib): Phase 1/2 readout est. (NCT04774393)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 1/2\, Acute Myeloid Leukemia.\nStu
 dy: Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib 
 or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Le
 ukemia\nEstimated primary completion: 29 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04774393
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05586074-3016@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Clifutinib Besylate: Phase 3 readout est. (NCT05586074)
DESCRIPTION:Clifutinib Besylate\, phase 3\, Acute Myeloid Leukemia.\nStudy:
  HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML\nEstimated prima
 ry completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/clifutinib-besylate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05586074
URL:https://assetmemo.bio/drug/clifutinib-besylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04581512-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04581512)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study 
 to Evaluate the Safety and Tolerability of EP0042\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04581512
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04581512-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04581512)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  to Evaluate the Safety and Tolerability of EP0042\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04581512
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04581512-2903@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Mobinitinib: Phase 1/2 readout est. (NCT04581512)
DESCRIPTION:Mobinitinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  to Evaluate the Safety and Tolerability of EP0042\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/mobinitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04581512
URL:https://assetmemo.bio/drug/mobinitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06470841-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06470841)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: CHG Comb
 ined With Venetoclax and Azacytidine in Newly Diagnosed AML\nEstimated pri
 mary completion: December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06470841
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06470841-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06470841)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: CHG Com
 bined With Venetoclax and Azacytidine in Newly Diagnosed AML\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06470841
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02781883-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02781883)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Clinical
  Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AM
 L\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02781883
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02781883-2931@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Prexigebersen: Phase 2 readout est. (NCT02781883)
DESCRIPTION:Prexigebersen\, phase 2\, Acute Myeloid Leukemia.\nStudy: Clini
 cal Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in
  AML\nEstimated primary completion: December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/prexigebersen#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT02781883
URL:https://assetmemo.bio/drug/prexigebersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255872-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07255872)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stud
 y of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax 
 + Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07255872
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255872-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07255872)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax
  + Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07255872
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255872-2893@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BL-M11D1: Phase 2/3 readout est. (NCT07255872)
DESCRIPTION:BL-M11D1\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Study 
 of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + 
 Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated primary com
 pletion: December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bl-m11d1#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07255872
URL:https://assetmemo.bio/drug/bl-m11d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548230-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06548230)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phas
 e 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without
  Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Mye
 logenous Leukemia (AML)\nEstimated primary completion: 1 December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06548230
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548230-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT06548230)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Pha
 se 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Withou
 t Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute My
 elogenous Leukemia (AML)\nEstimated primary completion: 1 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06548230
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744556-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06744556)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: HAV Vers
 us DAV/IAV Induction Regimen in Elderly Patients With AML\nEstimated prima
 ry completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06744556
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744556-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06744556)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: HAV Ver
 sus DAV/IAV Induction Regimen in Elderly Patients With AML\nEstimated prim
 ary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06744556
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304011-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07304011)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutasi
 denib With Azacitidine Followed by Olutasidenib Maintenance for the Treatm
 ent of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatmen
 t With Venetoclax Plus a Hypomethylating Agent\nEstimated primary completi
 on: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07304011
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304011-2857@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07304011)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutas
 idenib With Azacitidine Followed by Olutasidenib Maintenance for the Treat
 ment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatme
 nt With Venetoclax Plus a Hypomethylating Agent\nEstimated primary complet
 ion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /olutasidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07304011
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04065399-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT04065399)
DESCRIPTION:Revumenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rear
 rangement or NPM1 Mutation\nEstimated primary completion: 15 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04065399
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01409161-2842@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271218
DTEND;VALUE=DATE:20271219
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT01409161)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in
  Treating Patients With Previously Untreated Acute Promyelocytic Leukemia\
 nEstimated primary completion: 18 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT01409161
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01409161-3071@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271218
DTEND;VALUE=DATE:20271219
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT01409161)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in 
 Treating Patients With Previously Untreated Acute Promyelocytic Leukemia\n
 Estimated primary completion: 18 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tretinoin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT01409161
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07008638-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Vyxeos: Phase 1/2 readout est. (NCT07008638)
DESCRIPTION:Vyxeos\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Phase I/II
  Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for th
 e Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)\n
 Estimated primary completion: 30 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07008638
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04128748-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quizartinib: Phase 1/2 readout est. (NCT04128748)
DESCRIPTION:Quizartinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Lipos
 omal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatme
 nt of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/quizartinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04128748
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04128748-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vyxeos: Phase 1/2 readout est. (NCT04128748)
DESCRIPTION:Vyxeos\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Liposomal 
 Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of
  Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome\nEstimated 
 primary completion: 31 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04128748
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04797767-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04797767)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade
  Myeloid Neoplasms\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04797767
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270200-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05270200)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Singl
 e Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of
  Acute Myelogenous Leukemia Relapse\nEstimated primary completion: 31 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 270200
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04047641-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quizartinib: Phase 1/2 readout est. (NCT04047641)
DESCRIPTION:Quizartinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Cladr
 ibine\, Idarubicin\, Cytarabine\, and Quizartinib in Treating Patients Wit
 h Newly Diagnosed\, Relapsed\, or Refractory Acute Myeloid Leukemia or Hig
 h-Risk Myelodysplastic Syndrome\nEstimated primary completion: 31 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/quizartinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT040476
 41
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07036250-2970@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:U32 CAR-T: Phase 1/2 readout est. (NCT07036250)
DESCRIPTION:U32 CAR-T\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Clinica
 l Study of U32 in Patients With Acute Myeloid Leukemia\nEstimated primary 
 completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/u32-car-t#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07036250
URL:https://assetmemo.bio/drug/u32-car-t#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05133882-3016@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Clifutinib Besylate: Phase 1/2 readout est. (NCT05133882)
DESCRIPTION:Clifutinib Besylate\, phase 1/2\, Acute Myeloid Leukemia.\nStud
 y: A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Ch
 emotherapy in the Treatment of Newly Diagnosed AML\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/clifutinib-besylate#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05133882
URL:https://assetmemo.bio/drug/clifutinib-besylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761171-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Revumenib: Phase 2 readout est. (NCT05761171)
DESCRIPTION:Revumenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study o
 f Revumenib in Combination With Chemotherapy for Patients Diagnosed With R
 elapsed or Refractory Leukemia\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05761171
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04093570-2362@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT04093570
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2\, Acute Myeloid Leuk
 emia.\nStudy: A Study for Participants Who Participated in Prior Clinical 
 Studies of ASTX727 (Standard Dose)\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/decitabine-
 cedazuridine-inqovi#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04093570
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748455-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07748455)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: HMA-Vene
 toclax Induction in Newly Diagnosed AML\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/veneto
 clax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07748455
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862517-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07862517)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing 
 the Investigational Medication Combination of Azacitidine\, Venetoclax\, a
 nd Quizartinib Compared to the Usual Treatment of Cytarabine\, Daunorubici
 n\, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukem
 ia (A MyeloMATCH Treatment Trial)\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07862
 517
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748455-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07748455)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: HMA-Ven
 etoclax Induction in Newly Diagnosed AML\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaci
 tidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07748455
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862517-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07862517)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing
  the Investigational Medication Combination of Azacitidine\, Venetoclax\, 
 and Quizartinib Compared to the Usual Treatment of Cytarabine\, Daunorubic
 in\, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leuke
 mia (A MyeloMATCH Treatment Trial)\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 62517
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862517-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quizartinib: Phase 2 readout est. (NCT07862517)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing
  the Investigational Medication Combination of Azacitidine\, Venetoclax\, 
 and Quizartinib Compared to the Usual Treatment of Cytarabine\, Daunorubic
 in\, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leuke
 mia (A MyeloMATCH Treatment Trial)\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/quizartinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 62517
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554393-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05554393)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Comparin
 g Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Ven
 etoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermedi
 ate Risk AML (A MyeloMATCH Treatment Trial)\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05554393
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06621199-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06621199)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Mitoxant
 rone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax 
 Regimen in Newly Diagnosed Elderly AML\nEstimated primary completion: 31 D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06621199
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554393-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05554393)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Compari
 ng Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Ve
 netoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermed
 iate Risk AML (A MyeloMATCH Treatment Trial)\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 zacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05554393
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03589729-2842@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT03589729)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of C
 hemotherapy in Participants With Blood Cancers\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /gemtuzumab-ozogamicin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03589729
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04708054-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT04708054)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With
  High-Risk AML and MDS\nEstimated primary completion: 31 December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04708054
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392242-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07392242)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of the Combination of Ivosidenib\, Azacitidine\, and Venetoclax Followed b
 y Ivosidenib Alone in People With Acute Myeloid Leukemia\nEstimated primar
 y completion: January 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07392242
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392242-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07392242)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  of the Combination of Ivosidenib\, Azacitidine\, and Venetoclax Followed 
 by Ivosidenib Alone in People With Acute Myeloid Leukemia\nEstimated prima
 ry completion: January 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07392242
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392242-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07392242)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : A Study of the Combination of Ivosidenib\, Azacitidine\, and Venetoclax 
 Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia\nEstima
 ted primary completion: January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07392242
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03661307-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03661307)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Quizar
 tinib\, Decitabine\, and Venetoclax in Treating Participants With Untreate
 d or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
 \nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03661307
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03661307-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Quizartinib: Phase 1/2 readout est. (NCT03661307)
DESCRIPTION:Quizartinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Quiza
 rtinib\, Decitabine\, and Venetoclax in Treating Participants With Untreat
 ed or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrom
 e\nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/quizartinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03661307
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06707493-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT06707493)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Ivosidenib as Post-HSCT Maintenance for AML\nEstimated primary completio
 n: 1 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iv
 osidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06707493
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05010122-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Gilteritinib: Phase 1/2 readout est. (NCT05010122)
DESCRIPTION:Gilteritinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: ASTX
 727\, Venetoclax\, and Gilteritinib for the Treatment of Newly Diagnosed\,
  Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk M
 yelodysplastic Syndrome\nEstimated primary completion: 30 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05010122
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05010122-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05010122)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: ASTX72
 7\, Venetoclax\, and Gilteritinib for the Treatment of Newly Diagnosed\, R
 elapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Mye
 lodysplastic Syndrome\nEstimated primary completion: 30 January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05010122
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05010122-2362@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1/2 readout est. (NCT050101
 22)
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1/2\, Acute Myeloid Le
 ukemia.\nStudy: ASTX727\, Venetoclax\, and Gilteritinib for the Treatment 
 of Newly Diagnosed\, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leu
 kemia or High-Risk Myelodysplastic Syndrome\nEstimated primary completion:
  30 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dec
 itabine-cedazuridine-inqovi#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05010122
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930352-2835@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ziftomenib: Phase 2 readout est. (NCT06930352)
DESCRIPTION:Ziftomenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Ziftomen
 ib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acu
 te Myeloid Leukemia Not Eligible for Standard Therapy\nEstimated primary c
 ompletion: 31 January 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ziftomenib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06930352
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407660-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07407660)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Shortene
 d Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in
  Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus
  Venetoclax\nEstimated primary completion: 1 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07407660
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407660-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07407660)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Shorten
 ed Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy i
 n Elderly or Frail Patients With AML Patients Treated With Azacitidine Plu
 s Venetoclax\nEstimated primary completion: 1 February 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07407660
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456463-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06456463)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults Wi
 th Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Ch
 emotherapy\nEstimated primary completion: 9 February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06456463
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456463-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06456463)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults W
 ith Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive C
 hemotherapy\nEstimated primary completion: 9 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06456463
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456463-2839@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Tagraxofusp: Phase 2 readout est. (NCT06456463)
DESCRIPTION:Tagraxofusp\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults W
 ith Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive C
 hemotherapy\nEstimated primary completion: 9 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tagraxofusp#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06456463
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03850418-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Azacitidine: Phase 2 readout est. (NCT03850418)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Azaciti
 dine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Trans
 plant\nEstimated primary completion: 20 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03850418
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505160-2883@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT07505160)
DESCRIPTION:Lisaftoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Efficac
 y and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Vene
 toclax/Azacitidine Pretreated AML Patients\nEstimated primary completion: 
 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lisaftocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7505160
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507825-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07507825)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Explorat
 ory Study of Venetoclax\, Homoharringtonine\, Azacitidine Plus G-CSF for N
 ewly Diagnosed AML (VHAG)\nEstimated primary completion: 31 March 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07507825
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507825-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07507825)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Explora
 tory Study of Venetoclax\, Homoharringtonine\, Azacitidine Plus G-CSF for 
 Newly Diagnosed AML (VHAG)\nEstimated primary completion: 31 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07507825
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783100-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07783100)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax\, Chidamide\, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Re
 fractory Acute Myeloid Leukemia\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07783100
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469046-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07469046)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAH vs V
 A in Newly Diagnosed Elderly AML\nEstimated primary completion: 31 March 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07469046
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469046-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07469046)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAH vs 
 VA in Newly Diagnosed Elderly AML\nEstimated primary completion: 31 March 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0746904
 6
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514832-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07514832)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA-CIG R
 egimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Pros
 pective Single-Arm Trial\nEstimated primary completion: 1 April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07514832
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514832-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07514832)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA-CIG 
 Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Pro
 spective Single-Arm Trial\nEstimated primary completion: 1 April 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07514832
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07779031-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07779031)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Sin
 gle-Arm\, Open Phase I Clinical Study of Selinexor in Combination With Aza
 citidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT\n
 Estimated primary completion: 30 April 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07779031
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954987-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06954987)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoi
 etic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Ther
 apy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH
  Treatment Trial)\nEstimated primary completion: 15 May 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06954987
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389292-2883@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280525
DTEND;VALUE=DATE:20280526
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT06389292)
DESCRIPTION:Lisaftoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Pivot
 al Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatm
 ent of Acute Myeloid Leukemia\nEstimated primary completion: 25 May 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06389292
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07664839-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07664839)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study on
  the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly 
 Diagnosed AML With NPM1 or IDH1/IDH2 Mutations\nEstimated primary completi
 on: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vene
 toclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07664839
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07664839-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07664839)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study o
 n the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly
  Diagnosed AML With NPM1 or IDH1/IDH2 Mutations\nEstimated primary complet
 ion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aza
 citidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07664839
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463651-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Gilteritinib: Phase 3 readout est. (NCT07463651)
DESCRIPTION:Gilteritinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: MRD-gu
 ided Maintenance Post-HCT: Gilteritini vs Sorafenib\nEstimated primary com
 pletion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /gilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07463651
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05732103-3062@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rogocekib: Phase 1/2 readout est. (NCT05732103)
DESCRIPTION:Rogocekib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study
  of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk 
 Myelodysplastic Syndromes\nEstimated primary completion: June 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rogocekib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05732103
URL:https://assetmemo.bio/drug/rogocekib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668558-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06668558)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax + Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated primar
 y completion: June 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06668558
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668558-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06668558)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax + Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated prima
 ry completion: June 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06668558
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867626-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07867626)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Phase II
  De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax
  in AML\nEstimated primary completion: June 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07867626
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471841-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07471841)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutasi
 denib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received V
 enetoclax\nEstimated primary completion: June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07471841
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06262438-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Quizartinib: Phase 2 readout est. (NCT06262438)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: CHIP-AM
 L22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric F
 LT3-ITD+ and NPM1wt AML Patients\nEstimated primary completion: June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/quizartinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06262438
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471841-2857@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07471841)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutas
 idenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received 
 Venetoclax\nEstimated primary completion: June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07471841
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07597941-2883@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Lisaftoclax: Phase 2/3 readout est. (NCT07597941)
DESCRIPTION:Lisaftoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Lisaf
 toclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Le
 ukemia Patients\nEstimated primary completion: June 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07597941
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05404906-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT05404906)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: AZA + 
 Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remi
 ssion\nEstimated primary completion: June 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05404906
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05404906-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT05404906)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: AZA +
  Venetoclax as Maintenance Therapy in Younger Adults With AML in First Rem
 ission\nEstimated primary completion: June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05404906
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642453-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07642453)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA-CAG T
 wo-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed 
 Acute Myeloid Leukemia.\nEstimated primary completion: 1 June 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07642453
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642453-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07642453)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA-CAG 
 Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed
  Acute Myeloid Leukemia.\nEstimated primary completion: 1 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07642453
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04493164-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT04493164)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid L
 eukemia or High-Risk Myelodysplastic Syndrome\nEstimated primary completio
 n: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivosi
 denib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04493164
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04493164-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Vyxeos: Phase 2 readout est. (NCT04493164)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: CPX-351 and 
 Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or Hig
 h-Risk Myelodysplastic Syndrome\nEstimated primary completion: 1 June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/vyxeos#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04493164
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824168-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Quizartinib: Phase 2 readout est. (NCT06824168)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Evaluat
 ion of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute
  Myeloid Leukemia Patients in Complete Remission\nEstimated primary comple
 tion: 6 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qu
 izartinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06824168
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605949-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07605949)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Revumeni
 b\, Azacitidine\, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML\n
 Estimated primary completion: July 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07605949
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605949-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07605949)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Revumen
 ib\, Azacitidine\, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML\
 nEstimated primary completion: July 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07605949
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605949-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Revumenib: Phase 2 readout est. (NCT07605949)
DESCRIPTION:Revumenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Revumenib
 \, Azacitidine\, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML\nE
 stimated primary completion: July 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/revumenib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07605949
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05199051-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT05199051)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phas
 e 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults
  With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML\nEstimated pri
 mary completion: 10 July 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/gilteritinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05199051
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05199051-2842@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT05199051)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination 
 in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML\nEsti
 mated primary completion: 10 July 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05199051
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07735117-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280720
DTEND;VALUE=DATE:20280721
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07735117)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Mitoxant
 rone Hydrochloride Liposome\, Cytarabine\, G-CSF Plus Venetoclax vs. Azaci
 tidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML\nEstimated pr
 imary completion: 20 July 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07735117
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05520567-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Gilteritinib: Phase 1/2 readout est. (NCT05520567)
DESCRIPTION:Gilteritinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A St
 udy of Gilteritinib\, Venetoclax and Azacitidine as a Combined Treatment f
 or People Newly Diagnosed With Acute Myeloid Leukemia\nEstimated primary c
 ompletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/gilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05520567
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05520567-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05520567)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stud
 y of Gilteritinib\, Venetoclax and Azacitidine as a Combined Treatment for
  People Newly Diagnosed With Acute Myeloid Leukemia\nEstimated primary com
 pletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05520567
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05520567-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05520567)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy of Gilteritinib\, Venetoclax and Azacitidine as a Combined Treatment fo
 r People Newly Diagnosed With Acute Myeloid Leukemia\nEstimated primary co
 mpletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05520567
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06664879-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT06664879)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: ALLG 
 AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and 
 Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm\, Precision-b
 ased\, Recursive\, Platform Trial\nEstimated primary completion: 31 July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06664879
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667973-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT06667973)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Effica
 cy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-p
 ositive Acute Myeloid Leukemia\nEstimated primary completion: August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06667973
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05260528-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280802
DTEND;VALUE=DATE:20280803
SUMMARY:Vyxeos: Phase 2 readout est. (NCT05260528)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: CPX-351 vs I
 ntensive Chemotherapy in Patients With de Novo Intermediate or Adverse Ris
 k AML Stratified by Genomics\nEstimated primary completion: 2 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/vyxeos#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05260528
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04771130-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04771130)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy of BGB-11417 in Participants With Myeloid Malignancies\nEstimated prima
 ry completion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04771130
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04771130-2909@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT04771130)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Acute Myeloid Leukemia.\nSt
 udy: A Study of BGB-11417 in Participants With Myeloid Malignancies\nEstim
 ated primary completion: 31 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04771130
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501120-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04501120)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Pa
 tients Relapsed/Refractory AML\nEstimated primary completion: September 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04501120
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501120-2883@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Lisaftoclax: Phase 1/2 readout est. (NCT04501120)
DESCRIPTION:Lisaftoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Pa
 tients Relapsed/Refractory AML\nEstimated primary completion: September 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04501120
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501120-2925@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Olverembatinib: Phase 1/2 readout est. (NCT04501120)
DESCRIPTION:Olverembatinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: St
 udy of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in
  Patients Relapsed/Refractory AML\nEstimated primary completion: September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/olverembatinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT045
 01120
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140487-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Gilteritinib: Phase 1/2 readout est. (NCT04140487)
DESCRIPTION:Gilteritinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Azac
 itidine\, Venetoclax\, and Gilteritinib in Treating Patients With Recurren
 t/Refractory FLT3-Mutated Acute Myeloid Leukemia\, Chronic Myelomonocytic 
 Leukemia\, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neopla
 sm\nEstimated primary completion: 1 September 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04140487
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140487-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04140487)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Azacit
 idine\, Venetoclax\, and Gilteritinib in Treating Patients With Recurrent/
 Refractory FLT3-Mutated Acute Myeloid Leukemia\, Chronic Myelomonocytic Le
 ukemia\, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
 \nEstimated primary completion: 1 September 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04140487
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140487-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04140487)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Azaci
 tidine\, Venetoclax\, and Gilteritinib in Treating Patients With Recurrent
 /Refractory FLT3-Mutated Acute Myeloid Leukemia\, Chronic Myelomonocytic L
 eukemia\, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplas
 m\nEstimated primary completion: 1 September 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04140487
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680752-3039@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:ARD103: Phase 1/2 readout est. (NCT06680752)
DESCRIPTION:ARD103\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Clinical S
 tudy of ARD103 CAR-T Therapy for Patients With R/R AML or MDS\nEstimated p
 rimary completion: October 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ard103#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06680752
URL:https://assetmemo.bio/drug/ard103#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425808-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Gilteritinib: Phase 2/3 readout est. (NCT07425808)
DESCRIPTION:Gilteritinib\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: FLT3
 -ITD Targeted Therapy in Fit AML Patients\nEstimated primary completion: 1
  October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gilter
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07425808
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425808-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07425808)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: FLT3-I
 TD Targeted Therapy in Fit AML Patients\nEstimated primary completion: 1 O
 ctober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7425808
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425808-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07425808)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: FLT3-
 ITD Targeted Therapy in Fit AML Patients\nEstimated primary completion: 1 
 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaciti
 dine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07425808
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00801489-2842@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281011
DTEND;VALUE=DATE:20281012
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT00801489)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Fludarabine Phosphate\, Cytarabine\, Filgrastim-sndz\, Gemtuzumab Ozoga
 micin\, and Idarubicin Hydrochloride in Treating Patients With Newly Diagn
 osed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome\nEstimat
 ed primary completion: 11 October 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT00801489
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04067336-2835@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Ziftomenib: Phase 1/2 readout est. (NCT04067336)
DESCRIPTION:Ziftomenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: First 
 in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leuke
 mia\nEstimated primary completion: 16 October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ziftomenib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04067336
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04746235-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04746235)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax and ASTX727 for the Treatment of Relapsed\, Refractory\, or Newly Diagn
 osed Acute Myeloid Leukemia\nEstimated primary completion: 31 October 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04746235
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04746235-2362@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT04746235
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2\, Acute Myeloid Leuk
 emia.\nStudy: Venetoclax and ASTX727 for the Treatment of Relapsed\, Refra
 ctory\, or Newly Diagnosed Acute Myeloid Leukemia\nEstimated primary compl
 etion: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/decitabine-cedazuridine-inqovi#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04746235
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06557421-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06557421)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: De-Escal
 ation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML R
 esponding Patients\nEstimated primary completion: 1 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06557421
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06557421-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06557421)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: De-Esca
 lation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML 
 Responding Patients\nEstimated primary completion: 1 November 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06557421
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425782-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281126
DTEND;VALUE=DATE:20281127
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07425782)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax Combined With Azacitidine for Consolidation Therapy in AML\nEstimated p
 rimary completion: 26 November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07425782
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221683-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT06221683)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Clinic
 al Study of Induction Therapy Options Based on Molecular Subtyping and MRD
  in Children and Adolescents With AML\nEstimated primary completion: Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gilteritini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 221683
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06014489-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06014489)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Trial 
 to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in
  Adult Patients With Newly Diagnosed AML\nEstimated primary completion: De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6014489
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221683-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06221683)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Clinical
  Study of Induction Therapy Options Based on Molecular Subtyping and MRD i
 n Children and Adolescents With AML\nEstimated primary completion: Decembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062216
 83
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060001-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07060001)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Efficacy
  of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leu
 kemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker\nEstimat
 ed primary completion: December 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07060001
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06014489-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06014489)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Trial
  to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine i
 n Adult Patients With Newly Diagnosed AML\nEstimated primary completion: D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaciti
 dine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06014489
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060001-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07060001)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Efficac
 y of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Le
 ukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker\nEstima
 ted primary completion: December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07060001
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075016-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07075016)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Ivosiden
 ib and Azacitidine With or Without Venetoclax in Adult Patients With Newly
  Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive
  Chemotherapy\nEstimated primary completion: December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07075016
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646821-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281211
DTEND;VALUE=DATE:20281212
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07646821)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Pha
 se 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML W
 ith TP53 Mutations\nEstimated primary completion: 11 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07646821
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937124-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281214
DTEND;VALUE=DATE:20281215
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07937124)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : An All-Oral Combination of Ivosidenib\, Sonrotoclax\, and Chidamide for 
 Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC)\nEstima
 ted primary completion: 14 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07937124
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937124-2909@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281214
DTEND;VALUE=DATE:20281215
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07937124)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: An All-Oral Combination of Ivosidenib\, Sonrotoclax\, and Chidamide for
  Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC)\nEstim
 ated primary completion: 14 December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07937124
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07148180-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07148180)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Mult
 i-Site Break Through Cancer Trial: Targeting Measurable Residual Disease i
 n Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp\,
  Azacitidine\, and Venetoclax\nEstimated primary completion: 31 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07148180
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07148180-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07148180)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Mul
 ti-Site Break Through Cancer Trial: Targeting Measurable Residual Disease 
 in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp\
 , Azacitidine\, and Venetoclax\nEstimated primary completion: 31 December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0714818
 0
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07148180-2839@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tagraxofusp: Phase 1/2 readout est. (NCT07148180)
DESCRIPTION:Tagraxofusp\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Mul
 ti-Site Break Through Cancer Trial: Targeting Measurable Residual Disease 
 in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp\
 , Azacitidine\, and Venetoclax\nEstimated primary completion: 31 December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tagraxofusp#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0714818
 0
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07259707-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT07259707)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilter
 itinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed F
 LT3-ITD+ AML\nEstimated primary completion: 31 December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07259707
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07356154-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290116
DTEND;VALUE=DATE:20290117
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT07356154)
DESCRIPTION:Revumenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Revumenib and Mezigdomide in People With Leukemia\nEstimated primary c
 ompletion: 16 January 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/revumenib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07356154
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084819-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06084819)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Clinical
  Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relap
 sed/Refractory Acute Myeloid Leukemia\nEstimated primary completion: 31 Ja
 nuary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 084819
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07157514-3053@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:131I-apamistamab: Phase 2/3 readout est. (NCT07157514)
DESCRIPTION:131I-apamistamab\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: 
 Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Tran
 splant in Relapse/Refractory AML\nEstimated primary completion: February 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/131i-apamistamab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 57514
URL:https://assetmemo.bio/drug/131i-apamistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07423104-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07423104)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Cladribine\, Low Dose Cytarabine\, and Venetoclax in Treatment of Relap
 sed/Refractory or Secondary Acute Myeloid Leukemia\nEstimated primary comp
 letion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07423104
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407140-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Gilteritinib: Phase 3 readout est. (NCT07407140)
DESCRIPTION:Gilteritinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAG Ve
 rsus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3
 -Mutated AML\nEstimated primary completion: 1 February 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07407140
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407140-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07407140)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAG Vers
 us Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-M
 utated AML\nEstimated primary completion: 1 February 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07407140
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407140-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07407140)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAG Ver
 sus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-
 Mutated AML\nEstimated primary completion: 1 February 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07407140
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155226-2990@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:AZD3632: Phase 1/2 readout est. (NCT07155226)
DESCRIPTION:AZD3632\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study of 
 AZD3632 Monotherapy or in Combination With Anticancer Agents in Participan
 ts With Advanced Haematologic Malignancies With KMT2Ar\, NPM1m\, or Other 
 Genotypes Associated With HOX Overexpression\nEstimated primary completion
 : 15 February 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 zd3632#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07155226
URL:https://assetmemo.bio/drug/azd3632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04628026-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Venetoclax: Phase 3 readout est. (NCT04628026)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Phase II
 I Study of Induction and Consolidation Chemotherapy With Venetoclax in Pat
 ients With Newly Diagnosed AML or MDS-EB-2\nEstimated primary completion: 
 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 628026
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782542-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06782542)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutasid
 enib\, Venetoclax\, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute 
 Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy\nE
 stimated primary completion: 31 March 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06782542
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782542-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06782542)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutasi
 denib\, Venetoclax\, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute
  Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy\n
 Estimated primary completion: 31 March 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06782542
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782542-2857@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT06782542)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutas
 idenib\, Venetoclax\, and Azacitidine in IDH1 Mutated Newly Diagnosed Acut
 e Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy\
 nEstimated primary completion: 31 March 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06782542
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696183-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT06696183)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilter
 itinib in Combination With Venetoclax and Azacitidine for AML Patients Wit
 h FLT3 Mutations Ineligible for Intensive Treatment\nEstimated primary com
 pletion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 gilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06696183
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696183-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06696183)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilterit
 inib in Combination With Venetoclax and Azacitidine for AML Patients With 
 FLT3 Mutations Ineligible for Intensive Treatment\nEstimated primary compl
 etion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06696183
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696183-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06696183)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilteri
 tinib in Combination With Venetoclax and Azacitidine for AML Patients With
  FLT3 Mutations Ineligible for Intensive Treatment\nEstimated primary comp
 letion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 zacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06696183
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507760-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07507760)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML 
 Patients\nEstimated primary completion: April 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07507760
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07757672-2909@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT07757672)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Acute Myeloid Leukemia.\nSt
 udy: Salvage Chemotherapy With Sonrotoclax\, Cladribine\, and Standard-dos
 e Cytarabine\, Sequentially Followed by HSCT for R/R AML.\nEstimated prima
 ry completion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07757672
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05807932-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05807932)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax in Addition to Sequential Conditioning With Fludarabine / Amsacrine /
  Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantatio
 n in Patients With MDS\, CMML or sAML\nEstimated primary completion: 30 Ap
 ril 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0580
 7932
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023588-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07023588)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study on
  Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on
  Early Peripheral Blood Minimal Residual Disease\nEstimated primary comple
 tion: May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venet
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07023588
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOM
 ATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatmen
 t Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screen
 ing Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317649-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT06317649)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute M
 yeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)\nEstimated primary co
 mpletion: 15 May 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/gilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06317649
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOMAT
 CH: A Screening Study to Assign People With Myeloid Cancer to a Treatment 
 Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screenin
 g Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317649-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06317649)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Mye
 loid Leukemia (AML) (A MyeloMATCH Treatment Trial)\nEstimated primary comp
 letion: 15 May 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06317649
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOMA
 TCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment
  Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screeni
 ng Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317649-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06317649)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute My
 eloid Leukemia (AML) (A MyeloMATCH Treatment Trial)\nEstimated primary com
 pletion: 15 May 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06317649
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Quizartinib: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOMA
 TCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment
  Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screeni
 ng Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/quizartinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2857@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOM
 ATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatmen
 t Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screen
 ing Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2867@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT05564390)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a T
 reatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH
  Screening Trial)\nEstimated primary completion: 15 May 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Vyxeos: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOMATCH: 
 A Screening Study to Assign People With Myeloid Cancer to a Treatment Stud
 y or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Tr
 ial)\nEstimated primary completion: 15 May 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2947@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Emavusertib: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Emavusertib\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOMA
 TCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment
  Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screeni
 ng Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/emavusertib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03591510-2843@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290518
DTEND;VALUE=DATE:20290519
SUMMARY:Rydapt (Midostaurin): Phase 2 readout est. (NCT03591510)
DESCRIPTION:Rydapt (Midostaurin)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : A Global Study of Midostaurin in Combination With Chemotherapy to Evalua
 te Safety\, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Pat
 ients With FLT3 Mutated AML\nEstimated primary completion: 18 May 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/midostaurin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03591510
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471789-2868@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:CART84: Phase 1/2 readout est. (NCT07471789)
DESCRIPTION:CART84\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Safety and
  Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leu
 kemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).\nEstimate
 d primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cart84#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07471789
URL:https://assetmemo.bio/drug/cart84#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07211958-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Revumenib: Phase 3 readout est. (NCT07211958)
DESCRIPTION:Revumenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Study of 
 Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Ac
 ute Myeloid Leukemia (AML) With a NPM1 Mutation\nEstimated primary complet
 ion: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/revum
 enib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07211958
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06852222-3019@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290622
DTEND;VALUE=DATE:20290623
SUMMARY:bleximenib: Phase 3 readout est. (NCT06852222)
DESCRIPTION:bleximenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Bleximenib\, Venetoclax and Azacitidine For Treatment of Participants W
 ith Newly Diagnosed Acute Myeloid Leukemia (AML)\nEstimated primary comple
 tion: 22 June 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 leximenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06852222
URL:https://assetmemo.bio/drug/bleximenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228273-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290624
DTEND;VALUE=DATE:20290625
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07228273)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Inductio
 n and Consolidation With Fludarabine\, Cytarabine\, Idarubicin\, and Venet
 oclax for the Treatment of Acute Myeloid Leukemia\nEstimated primary compl
 etion: 24 June 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07228273
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04293562-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Gilteritinib: Phase 3 readout est. (NCT04293562)
DESCRIPTION:Gilteritinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Stud
 y to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilterit
 inib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations\
 nEstimated primary completion: 30 June 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04293562
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04293562-2842@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Gemtuzumab Ozogamicin: Phase 3 readout est. (NCT04293562)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 3\, Acute Myeloid Leukemia.\nStud
 y: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or
  Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 M
 utations\nEstimated primary completion: 30 June 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04293562
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04293562-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Vyxeos: Phase 3 readout est. (NCT04293562)
DESCRIPTION:Vyxeos\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study to C
 ompare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib f
 or Patients With Newly Diagnosed AML With or Without FLT3 Mutations\nEstim
 ated primary completion: 30 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04293562
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788756-10896@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Annamycin: Phase 2/3 readout est. (NCT06788756)
DESCRIPTION:Annamycin\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: L-Annam
 ycin for Injection in Combination With Cytarabine Injection as Second Line
  Therapy for Remission Induction in Adult Subjects With Refractory/Relapse
 d AML\nEstimated primary completion: August 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/annamycin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06788756
URL:https://assetmemo.bio/drug/annamycin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754799-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07754799)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Random
 ized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acut
 e Myeloid Leukemia\nEstimated primary completion: 30 September 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07754799
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754799-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07754799)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Rando
 mized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acu
 te Myeloid Leukemia\nEstimated primary completion: 30 September 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07754799
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755202-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT07755202)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilter
 itinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapse
 d/Refractory Leukemia\nEstimated primary completion: 1 October 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07755202
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755202-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07755202)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilterit
 inib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/
 Refractory Leukemia\nEstimated primary completion: 1 October 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07755202
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755202-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07755202)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilteri
 tinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed
 /Refractory Leukemia\nEstimated primary completion: 1 October 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07755202
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717958-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT06717958)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic St
 em Cell Transplantation in Patients With Acute Myeloid Leukemia or High-ri
 sk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutati
 on\nEstimated primary completion: 1 October 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06717958
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651163-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07651163)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Compa
 ring the Efficacy of LDA\, LHAA\, and LA Regimens in Young Adults With Int
 ermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Che
 motherapy\nEstimated primary completion: December 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07651163
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651176-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07651176)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Compa
 ring the Efficacy of the LDA\, LHAA\, and DA Regimens in Young Adults With
  Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy\nEsti
 mated primary completion: December 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07651176
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651163-2883@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lisaftoclax: Phase 2/3 readout est. (NCT07651163)
DESCRIPTION:Lisaftoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Compa
 ring the Efficacy of LDA\, LHAA\, and LA Regimens in Young Adults With Int
 ermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Che
 motherapy\nEstimated primary completion: December 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07651163
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651176-2883@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lisaftoclax: Phase 2/3 readout est. (NCT07651176)
DESCRIPTION:Lisaftoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Compa
 ring the Efficacy of the LDA\, LHAA\, and DA Regimens in Young Adults With
  Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy\nEsti
 mated primary completion: December 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07651176
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925190-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07925190)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study
  Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Unt
 reated Acute Myeloid Leukemia (AML) Patients\nEstimated primary completion
 : December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azac
 itidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07925190
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925190-2932@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Mesutoclax: Phase 3 readout est. (NCT07925190)
DESCRIPTION:Mesutoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study 
 Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untr
 eated Acute Myeloid Leukemia (AML) Patients\nEstimated primary completion:
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mesut
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07925190
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07508982-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291212
DTEND;VALUE=DATE:20291213
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07508982)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Phase
 1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML\nEstimated prim
 ary completion: 12 December 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07508982
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06652438-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291213
DTEND;VALUE=DATE:20291214
SUMMARY:Revumenib: Phase 3 readout est. (NCT06652438)
DESCRIPTION:Revumenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Revumenib
  in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or 
 KMT2A-rearranged AML\nEstimated primary completion: 13 December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06652438
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05143996-2986@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:CLN-049: Phase 1/2 readout est. (NCT05143996)
DESCRIPTION:CLN-049\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: CLN-049 i
 n Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelod
 ysplastic Syndrome (MDS)\nEstimated primary completion: 30 December 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cln-049#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05143996
URL:https://assetmemo.bio/drug/cln-049#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926607-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07926607)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Palboc
 iclib\, All-Trans Retinoic Acid\, and Venetoclax in Relapsed or Refractory
  Acute Myeloid Leukemia\nEstimated primary completion: 31 December 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07926607
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926607-3071@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Vesanoid (Tretinoin): Phase 1/2 readout est. (NCT07926607)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 1/2\, Acute Myeloid Leukemia.\nStu
 dy: Palbociclib\, All-Trans Retinoic Acid\, and Venetoclax in Relapsed or 
 Refractory Acute Myeloid Leukemia\nEstimated primary completion: 31 Decemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tretinoin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079266
 07
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949370-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT07949370)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phas
 e 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Sub
 jects With R/R AML\nEstimated primary completion: 31 December 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07949370
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949370-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07949370)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase 
 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subje
 cts With R/R AML\nEstimated primary completion: 31 December 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07949370
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949370-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07949370)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase
  2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subj
 ects With R/R AML\nEstimated primary completion: 31 December 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07949370
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949370-2839@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tagraxofusp: Phase 2 readout est. (NCT07949370)
DESCRIPTION:Tagraxofusp\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase
  2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subj
 ects With R/R AML\nEstimated primary completion: 31 December 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tagraxofusp#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07949370
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686107-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Revumenib: Phase 2 readout est. (NCT07686107)
DESCRIPTION:Revumenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Trial of 
 Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory N
 UP98-rearranged AML."\nEstimated primary completion: 31 December 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07686107
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949370-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Revumenib: Phase 2 readout est. (NCT07949370)
DESCRIPTION:Revumenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase 2
  Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjec
 ts With R/R AML\nEstimated primary completion: 31 December 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07949370
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07396480-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07396480)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Fludarab
 ine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan 
 Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantatio
 n in AML/MDS Patients Aged > 50 Years: a Multicenter\, Randomized\, Phase 
 3 Trial\nEstimated primary completion: 31 January 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07396480
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972641-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT06972641)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Molecu
 lar Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic 
 Stem Cell Transplantation\nEstimated primary completion: 31 March 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06972641
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07478991-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07478991)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Azacytid
 ine\, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Pat
 ients (VENP-A-QUI)\nEstimated primary completion: April 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07478991
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07478991-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07478991)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Azacyti
 dine\, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Pa
 tients (VENP-A-QUI)\nEstimated primary completion: April 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07478991
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07478991-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Quizartinib: Phase 3 readout est. (NCT07478991)
DESCRIPTION:Quizartinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Azacyti
 dine\, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Pa
 tients (VENP-A-QUI)\nEstimated primary completion: April 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/quizartinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07478991
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07539818-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07539818)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Azacitid
 ine + Venetoclax VS Azacitidineas Maintenance Therapy in AML\nEstimated pr
 imary completion: 1 April 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07539818
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153497-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300426
DTEND;VALUE=DATE:20300427
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07153497)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing 
 the Use of an IDH1 Inhibitor\, Olutasidenib\, in Acute Myeloid Leukemia Ad
 ded to ASTX727 and Venetoclax\; in High-Risk MDS Added to ASTX727\; and Al
 one in Low Risk MDS (A MyeloMATCH Treatment Substudy)\nEstimated primary c
 ompletion: 26 April 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07153497
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153497-2362@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300426
DTEND;VALUE=DATE:20300427
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT07153497
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2\, Acute Myeloid Leuk
 emia.\nStudy: Testing the Use of an IDH1 Inhibitor\, Olutasidenib\, in Acu
 te Myeloid Leukemia Added to ASTX727 and Venetoclax\; in High-Risk MDS Add
 ed to ASTX727\; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy
 )\nEstimated primary completion: 26 April 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07153497
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153497-2857@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300426
DTEND;VALUE=DATE:20300427
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07153497)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testin
 g the Use of an IDH1 Inhibitor\, Olutasidenib\, in Acute Myeloid Leukemia 
 Added to ASTX727 and Venetoclax\; in High-Risk MDS Added to ASTX727\; and 
 Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)\nEstimated primary
  completion: 26 April 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/olutasidenib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07153497
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770698-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07770698)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acut
 e Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia\nEstimated prim
 ary completion: 30 April 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07770698
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770698-2909@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT07770698)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Acute Myeloid Leukemia.\nSt
 udy: A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refra
 ctory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia\nEsti
 mated primary completion: 30 April 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07770698
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02115295-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT02115295)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Cladri
 bine\, Idarubicin\, Cytarabine\, and Venetoclax in Treating Patients With 
 Acute Myeloid Leukemia\, High-Risk Myelodysplastic Syndrome\, or Blastic P
 hase Chronic Myeloid Leukemia\nEstimated primary completion: 31 May 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT02115295
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02115295-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02115295)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Cladribi
 ne\, Idarubicin\, Cytarabine\, and Venetoclax in Treating Patients With Ac
 ute Myeloid Leukemia\, High-Risk Myelodysplastic Syndrome\, or Blastic Pha
 se Chronic Myeloid Leukemia\nEstimated primary completion: 31 May 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT02115295
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02115295-2843@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Rydapt (Midostaurin): Phase 2 readout est. (NCT02115295)
DESCRIPTION:Rydapt (Midostaurin)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Cladribine\, Idarubicin\, Cytarabine\, and Venetoclax in Treating Patien
 ts With Acute Myeloid Leukemia\, High-Risk Myelodysplastic Syndrome\, or B
 lastic Phase Chronic Myeloid Leukemia\nEstimated primary completion: 31 Ma
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/midostaurin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02115
 295
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07078591-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07078591)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax-containing Therapy Combined With Microtransplant for Newly Diagnosed AM
 L\nEstimated primary completion: June 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07078591
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07078591-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07078591)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax-containing Therapy Combined With Microtransplant for Newly Diagnosed A
 ML\nEstimated primary completion: June 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07078591
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223814-3019@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:bleximenib: Phase 3 readout est. (NCT07223814)
DESCRIPTION:bleximenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Bleximen
 ib in Combination With Standard Induction and Consolidation Therapy Follow
 ed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (A
 ML)\nEstimated primary completion: June 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/bleximenib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07223814
URL:https://assetmemo.bio/drug/bleximenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672262-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07672262)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA Conso
 lidation in Intermediate-Risk AML\nEstimated primary completion: 1 June 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07672262
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672262-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07672262)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA Cons
 olidation in Intermediate-Risk AML\nEstimated primary completion: 1 June 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07672262
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578247-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300626
DTEND;VALUE=DATE:20300627
SUMMARY:Quizartinib: Phase 3 readout est. (NCT06578247)
DESCRIPTION:Quizartinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Quizart
 inib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-IT
 D Negative AML\nEstimated primary completion: 26 June 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/quizartinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06578247
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05442216-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300721
DTEND;VALUE=DATE:20300722
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05442216)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Tagraxof
 usp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After
  Hypomethylating Agents\nEstimated primary completion: 21 July 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05442216
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05442216-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300721
DTEND;VALUE=DATE:20300722
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05442216)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Tagraxo
 fusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML Afte
 r Hypomethylating Agents\nEstimated primary completion: 21 July 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05442216
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05442216-2839@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300721
DTEND;VALUE=DATE:20300722
SUMMARY:Tagraxofusp: Phase 2 readout est. (NCT05442216)
DESCRIPTION:Tagraxofusp\, phase 2\, Acute Myeloid Leukemia.\nStudy: Tagraxo
 fusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML Afte
 r Hypomethylating Agents\nEstimated primary completion: 21 July 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tagraxofusp#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05442216
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686965-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300810
DTEND;VALUE=DATE:20300811
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07686965)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Lisafto
 clax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell
  Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relaps
 e\nEstimated primary completion: 10 August 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07686965
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686965-2883@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300810
DTEND;VALUE=DATE:20300811
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT07686965)
DESCRIPTION:Lisaftoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Lisafto
 clax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell
  Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relaps
 e\nEstimated primary completion: 10 August 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07686965
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06598384-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06598384)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA as Ma
 intenance Therapy Post Allo-HSCT in MDS and AML\nEstimated primary complet
 ion: September 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06598384
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06598384-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06598384)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA as M
 aintenance Therapy Post Allo-HSCT in MDS and AML\nEstimated primary comple
 tion: September 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06598384
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463768-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07463768)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib t
 o Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leuke
 mia (AML) and IDH1 Mutation\, in Complete Remission After Intensive Chemot
 herapy.\nEstimated primary completion: September 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07463768
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463768-11033@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Azacitidine (Onureg): Phase 2 readout est. (NCT07463768)
DESCRIPTION:Azacitidine (Onureg)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib t
 o Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leuke
 mia (AML) and IDH1 Mutation\, in Complete Remission After Intensive Chemot
 herapy.\nEstimated primary completion: September 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07463768
URL:https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05904106-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05904106)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Ne
 wly Diagnosed NPM1 Mutated AML\nEstimated primary completion: September 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05904106
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05904106-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05904106)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With N
 ewly Diagnosed NPM1 Mutated AML\nEstimated primary completion: September 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05904106
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604064-2857@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07604064)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Clin
 ical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia\nEstima
 ted primary completion: September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07604064
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082452-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07082452)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Multic
 enter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposur
 e To Seven Days Versus Standard Continuous Venetoclax Exposure Combined Wi
 th Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Wh
 o Are Ineligible for Intensive Induction\nEstimated primary completion: Se
 ptember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07082452
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082452-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07082452)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Multi
 center Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposu
 re To Seven Days Versus Standard Continuous Venetoclax Exposure Combined W
 ith Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia W
 ho Are Ineligible for Intensive Induction\nEstimated primary completion: S
 eptember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacit
 idine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07082452
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554419-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05554419)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing 
 the Use of Combination Therapy in Patients With Persistent Low Level Acute
  Myeloid Leukemia Following Initial Treatment\, The ERASE Study (A MyeloMA
 TCH Treatment Trial)\nEstimated primary completion: 31 December 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05554419
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554419-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05554419)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing
  the Use of Combination Therapy in Patients With Persistent Low Level Acut
 e Myeloid Leukemia Following Initial Treatment\, The ERASE Study (A MyeloM
 ATCH Treatment Trial)\nEstimated primary completion: 31 December 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05554419
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554419-2901@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Vyxeos: Phase 2 readout est. (NCT05554419)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing the 
 Use of Combination Therapy in Patients With Persistent Low Level Acute Mye
 loid Leukemia Following Initial Treatment\, The ERASE Study (A MyeloMATCH 
 Treatment Trial)\nEstimated primary completion: 31 December 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/vyxeos#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05554419
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563010-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Revumenib: Phase 2 readout est. (NCT07563010)
DESCRIPTION:Revumenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Menin-Inh
 ibitor Targeted Maintenance in AML\nEstimated primary completion: June 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07563010
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604233-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20310603
DTEND;VALUE=DATE:20310604
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07604233)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Phase 
 1/2 FLAG-IDA\, VEN and Asciminib in CML and Ph+ AML\nEstimated primary com
 pletion: 3 June 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07604233
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431257-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20310901
DTEND;VALUE=DATE:20310902
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05431257)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Azacitid
 ine in Combination With Low Dose Intensity Venetoclax in Patients With AML
  Incl. Explorative AML Profiling\nEstimated primary completion: 1 Septembe
 r 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054312
 57
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710534-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07710534)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Metronom
 ic Decitabine-Cedazuridine and Venetoclax in R/R AML\, HR-MDS\, HR/AP MPN\
 nEstimated primary completion: 30 September 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07710534
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06969430-3027@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Debio 1562M: Phase 1/2 readout est. (NCT06969430)
DESCRIPTION:Debio 1562M\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy to Assess the Safety\, Tolerability\, and Antileukemic Activity of Debi
 o 1562M in Participants With Acute Myeloid Leukemia (AML)\nEstimated prima
 ry completion: November 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/debio-1562m#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06969430
URL:https://assetmemo.bio/drug/debio-1562m#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007312-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07007312)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Studies 
 to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With U
 ntreated NPM1-m or KMT2A-r AML\nEstimated primary completion: November 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007312
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007312-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07007312)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Studies
  to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With 
 Untreated NPM1-m or KMT2A-r AML\nEstimated primary completion: November 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007312
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007312-2835@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Ziftomenib: Phase 3 readout est. (NCT07007312)
DESCRIPTION:Ziftomenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Studies 
 to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With U
 ntreated NPM1-m or KMT2A-r AML\nEstimated primary completion: November 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007312
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02724163-2842@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Gemtuzumab Ozogamicin: Phase 3 readout est. (NCT02724163)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 3\, Acute Myeloid Leukemia.\nStud
 y: International Randomised Phase III Clinical Trial in Children With Acut
 e Myeloid Leukaemia\nEstimated primary completion: December 2031. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02724163
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581002-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07581002)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stud
 y to Assess Adverse Events and Change in Disease Activity When Intravenous
  (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and 
 IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Le
 ukemia (AML)\nEstimated primary completion: June 2032. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07581002
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581002-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07581002)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy to Assess Adverse Events and Change in Disease Activity When Intravenou
 s (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and
  IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid L
 eukemia (AML)\nEstimated primary completion: June 2032. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07581002
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581002-2846@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Decnupaz (Pivekimab Sunirine): Phase 2/3 readout est. (NCT07581002)
DESCRIPTION:Decnupaz (Pivekimab Sunirine)\, phase 2/3\, Acute Myeloid Leuke
 mia.\nStudy: A Study to Assess Adverse Events and Change in Disease Activi
 ty When Intravenous (IV) Pivekimab Sunirine is Given in Combination With O
 ral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants Wi
 th Acute Myeloid Leukemia (AML)\nEstimated primary completion: June 2032. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pivekimab-sunirine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075810
 02
URL:https://assetmemo.bio/drug/pivekimab-sunirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2038@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Gilteritinib: Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Gilteritinib\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Stud
 y of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated primar
 y completion: December 2032. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/gilteritinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03013998
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Study 
 of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated primary 
 completion: December 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03013998
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2832@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Study
  of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated primary
  completion: December 2032. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03013998
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2841@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Revumenib: Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Revumenib\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Study o
 f Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated primary c
 ompletion: December 2032. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/revumenib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03013998
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2867@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Idhifa (Enasidenib): Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2/3\, Acute Myeloid Leukemia.\nStud
 y: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated
  primary completion: December 2032. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/enasidenib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03013998
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2899@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Tibsovo (Ivosidenib): Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2/3\, Acute Myeloid Leukemia.\nStu
 dy: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimate
 d primary completion: December 2032. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03013998
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-3019@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:bleximenib: Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:bleximenib\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Study 
 of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated primary 
 completion: December 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bleximenib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03013998
URL:https://assetmemo.bio/drug/bleximenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07437950-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20340922
DTEND;VALUE=DATE:20340923
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07437950)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Comparin
 g Different Treatment Lengths for Venetoclax in Older People With Newly Di
 agnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)\nEstimated p
 rimary completion: 22 September 2034. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07437950
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07948122-2078@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07948122)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Prospect
 ive Evaluation of Response to Treatment in Younger Adult Patients (18-60 Y
 ears) With Acute Myeloid Leukemia (AML)\nEstimated primary completion: 31 
 December 2035. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/veneto
 clax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07948122
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07948122-2836@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Quizartinib: Phase 3 readout est. (NCT07948122)
DESCRIPTION:Quizartinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Prospec
 tive Evaluation of Response to Treatment in Younger Adult Patients (18-60 
 Years) With Acute Myeloid Leukemia (AML)\nEstimated primary completion: 31
  December 2035. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/quiza
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07948122
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07948122-2843@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Rydapt (Midostaurin): Phase 3 readout est. (NCT07948122)
DESCRIPTION:Rydapt (Midostaurin)\, phase 3\, Acute Myeloid Leukemia.\nStudy
 : Prospective Evaluation of Response to Treatment in Younger Adult Patient
 s (18-60 Years) With Acute Myeloid Leukemia (AML)\nEstimated primary compl
 etion: 31 December 2035. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/midostaurin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07948122
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
